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Abstract 
Oral delivery of peptides and proteins is hindered by their rapid proteolysis in the 
gastrointestinal tract and their inability to permeate biological membranes. Various drug 
delivery approaches are being investigated and implemented to overcome these obstacles. In 
the discussed study conducted in pigs, an investigation was undertaken to assess the effect of 
combination of a permeation enhancer – salcaprozate sodium, and a proteolysis inhibitor – 
soybean trypsin inhibitor, on the systemic exposure of the peptide teriparatide, following 
intraduodenal administration. Results demonstrate that this combination achieves significantly 
higher Cmax and AUC (~10- and ~20-fold respectively) compared to each of these 
methodologies on their own. It was thus concluded that an appropriate combination of different 
technological approaches may considerably contribute to an efficient oral delivery of biological 
macromolecules. 
 
Keywords: Oral delivery; Permeation enhancer; Pharmacokinetics; Salcaprozate sodium; SNAC; 
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The therapeutic reliance on peptide and protein drugs has expanded in the last three decades 
and continues to grow at an ever-fast pace (Fosgerau and Hoffmann 2015). Their potency and 
specific mode of action result in predictable responses, low toxicity, and minimal nonspecific 
and/or drug-drug interactions. All these characteristics make them particularly attractive as 











Oral route of administration is generally considered to be the preferred one for patients due to 
convenience, safety, and acceptance (Lennernäs et al. 2007). For people suffering from chronic 
diseases requiring frequent injections, such as diabetes, growth hormone deficiency and 
osteoporosis, the oral route of administration as a substitute to injection might be particularly 
attractive and is likely to increase compliance, adherence and improve the quality of life. 
However, oral delivery of biological drugs is a challenging undertaking given that their 
absorption is hampered by the inability to permeate the lipophilic membrane of the cells lining 
the gastrointestinal tract (GIT) due to their hydrophilic nature, large molecular size, and 
significant degradation by enzymes in the GIT (Smart, Gaisford, and Basit 2014; D.J. Brayden et 
al. 2020). These factors make the oral bioavailability of biological drugs negligible and clinically 
irrelevant. Thus, significant efforts are undertaken to enable the transfer of macromolecules 
from the parenteral to oral administration route. 
 
The research in the field of oral delivery is driven by the utilization of several methods, alas with 
only limited clinical success. These methods can be categorized into two main approaches 
(Aguirre et al. 2016): 1) prevention of proteolysis in the GIT, thereby enabling peptide and 
protein molecules to reach the membrane of epithelial cells intact, and 2) enhancement of the 
molecule’s permeation through the epithelial lining. Prevention of enzymatic degradation can 
be achieved by chemical modification of the drug molecule, inhibition of gastrointestinal 
peptidases, or physical protection of the drug. Permeation enhancement can be attained by the 
utilization of transcellular or paracellular permeation enhancing methods, as well as by chemical 
modifications of the drug molecule. 
 
A combination of these two main approaches enables further advances towards reaching the 
goal of oral delivery of biological drugs. This concept has been implemented, with promising 
results, by several clinical-stage biotech companies. Oramed Pharmaceuticals Inc. successfully 
enhances oral bioavailability of insulin by co-administration with a protease inhibitor and a Ca+ 
chelating agent, which increases paracellular permeability (Eldor, Kidron, and Arbit 2010; Eldor 
et al. 2013). Enhanced bioavailability of salmon calcitonin is achieved by Enteris BioPharma Inc. 
following co-administration with a pH modifying agent – citric acid, inhibiting the activity of 
digestive enzymes, and a paracellular permeation enhancer – acylcarnitine (Welling et al. 2014). 
Several additional clinical studies utilizing combinations of the two approaches can also be 
found in the literature (D.J. Brayden et al. 2020). 
 
Published data specifically evaluating this combination approach is lacking. Therefore, the 
current investigation was conducted with the objective to study the combined effect of the two 
approaches on the extent of systemic absorption following per oral administration of the 
peptide teriparatide (hPTH(1-34)).  
 
hPTH(1-34) is a bioactive peptide, comprised of the 34 amino acids from the N-terminus of 
human parathyroid hormone (PTH). PTH is important for calcium homeostasis. Exogenously 
administered hPTH(1-34) is used in the treatment of different forms of osteoporosis (Hock and 
Gera 1992) and is being researched as a treatment for hypoparathyroidism (Burshtein et al. 
2017). Forteo® is the first product utilizing hPTH(1-34) by subcutaneous injection, for the 











hPTH(1-34) is rapidly degraded by the GIT proteases pepsin, chymotrypsin, and trypsin as shown 
by Werle, Samhaber, and Bernkop-Schnürch (2006). In their work, it was also shown that other 
major GIT peptidases (namely: aminopeptidase N, elastase, and membrane-bound peptidases) 
had a very limited effect on the degradation of hPTH(1-34), making these enzymes not relevant 
for the time frame of hPTH(1-34) absorption. In addition, with a relatively high molecular weight 
of 4.12 kDa and very high hydrophilicity of LogP ~-18, hPTH(1-34) permeability through lipophilic 
membranes is very low. In the present work, hPTH(1-34) was co-formulated with either a 
permeation enhancer – salcaprozate sodium (SNAC), a protease inhibitor – soybean trypsin 
inhibitor (SBTI), or both. 
 
SNAC has been extensively investigated as an intestinal permeation enhancer of orally delivered 
macromolecules for more than 20 years (Twarog et al. 2019). This research culminated with the 
recent utilization of SNAC in the Novo Nordisk A/S product Rybelsus®, an oral tablet containing 
SNAC with a peptide drug semaglutide (Bucheit et al. 2020) and approved by FDA in late 2019. 
This product is considered to be the first oral combination of a peptide drug with a permeation 
enhancer, to reach the market.  
 
The permeation enhancement mechanism of action of SNAC has not been fully elucidated. SNAC 
is known to increase the passive transcellular permeation rate of co-administered active 
molecules through a transient increase in membrane fluidity of the cells lining the GIT (Alani and 
Robinson 2008; D. Brayden et al. 1997; Hess, Rotshild, and Hoffman 2005; Malkov et al. 2002; 
Twarog et al. 2019; Twarog et al. 2020). Additionally, this permeation enhancement effect 
requires a high local concentration of SNAC in close proximity to the intestinal wall (Hess, 
Rotshild, and Hoffman 2005; Twarog et al. 2019). The delivered drug must be in this zone of high 
SNAC concentration (Buckley et al. 2018; McIntyre et al. 2011). The increased permeability 
effect diminishes rapidly as SNAC’s local concentration declines, due to its dilution in fluids 
present in the lumen of the GIT and its own systemic absorption (Karsdal et al. 2015). As this 
local effect of SNAC is short-lasting, the time frame for the increase in the permeability of the 
active molecule is limited. It was also suggested (Buckley et al. 2018) that in the semaglutide 
formulation SNAC has a dual mode of action in the stomach. In addition to the permeability 
enhancement effect, it was proposed that SNAC also prevents proteolytic action of pepsin on 
the semaglutide by elevating the gastric pH. Absorption of hPTH(1-34) following oral 
administration was shown to be significantly augmented by SNAC in a comprehensive in vivo 
study in rats undertaken by Emisphere Technologies Inc. (Leone-Bay et al. 2001).  
 
SBTI is a protein found in soybeans, and is a potent inhibitor of the digestive proteolytic 
enzymes trypsin, chymotrypsin, and elastase (Birk 1976), the same enzymes which extensively 
degrade hPTH(1-34). SBTI acts as a competitive substrate, forming a complex with the digestive 
enzyme, which cannot be dissociated by the enzyme, thereby efficiently blocking its active site 
and protease activity (Laskowski and Kato 1980). When released concomitantly with the drug 
from the formulation, the action of local enzymatic inhibition will prevent the drug from fast 
degradation. SBTI is not a part of a commercial product. Nevertheless, numerous human trials 
were completed with SBTI (Hernández-Ledesma and Hsieh 2017; Burshtein et al. 2018b). Results 












The current work was aimed to study the combined effect of per oral co-administration of SNAC 
and SBTI on the systemic exposure of hPTH(1-34). This approach was tested in vivo in pigs, 
following direct intraduodenal administration.  
 
 




hPTH(1-34) acetate was purchased from Bachem (Bubendorf, Switzerland), L-(tosylamido-2-
phenyl) ethyl chloromethyl ketone (TPCK) treated bovine pancreas trypsin (I.U.B 3.4.21.4; 225 p-
toluene-sulfonyl-L-arginine methyl ester (TAME) units/mg solid) and tosyl-L-lysyl-chloromethane 
hydrochloride (TLCK) treated bovine pancreas chymotrypsin (I.U.B 3.4.21.1; 61.8 N-Benzoyl-L-
tyrosine ethyl ester (BTEE) units/mg solid) were purchased from Worthington Industries 
(Columbus, OH, US), SBTI (Bowman-Birk type, Mw=8000 gr/mol, 349.6 TAME units/mg solid) 
was purchased from BBI solutions (Blaenavon, UK), SNAC (assay=97.0 %) was produced by 
Entera Bio Ltd. (Jerusalem, Israel), lactose was purchased from Sigma (Jerusalem, Israel), 
magnesium stearate was kindly provided by Merck & Co (Darmstadt, Germany), HPLC grade 
acetonitrile was purchased from J.T Baker (Avantor Performance Materials, LLC, Radnor, PA, 
US), water was purified with a tandem RiOs (reverse osmosis)/Milli-Q Gradient A-10 system 
(Millipore, Molsheim, France), and all other chemicals were of analytical grade. 
 
2.2 Tested formulations 
 
Three different formulations were prepared according to Table 1 (based on (Ish-Shalom et al. 
2021) and (Burshtein et al. 2018a)). Formulations were prepared by geometrical mixing of 
constituents using a mortar and pestle, followed by dry granulation. The granulate was sifted 
and the fraction between sieves of 14 to 20 Mesh was collected and used in the study. Lactose 
was added instead of SNAC to the SBTI/hPTH(1-34) formulation as a filler to ensure similar final 
weight of the tested formulations. 
 
Table 1. Content of each formulation tested in the study. 
 Quantity in the formulation (%) 
Formulation ID hPTH(1-34) SNAC SBTI Lactose Mg stearate 
SNAC/SBTI/hPTH(1-34) 0.6 84.4 14.0 --- 1.0 
SNAC/hPTH(1-34) 0.6 98.4 --- --- 1.0 
SBTI/hPTH(1-34) 0.6 --- 14.0 84.4 1.0 
hPTH(1-34) – teriparatide (as acetate), SNAC – salcaprozate sodium, SBTI – soybean trypsin 
inhibitor.  
 
2.3 Dissolution test 
 
A dissolution test of 133 mg of each formulation was performed according to the USP 
compendial test <711> using apparatus II (Paddle) in 500 mL phosphate buffer pH 6.4 heated to 
37 oC, with a stirring rate of 50 RPM. 20 mL samples were withdrawn at time points: 0, 5, 10, 15, 
and 20 min. After each sampling, the dissolution media was replenished. Samples were filtered 
through a 13 mm Acrodisc Syringe Filter with 0.45 µm Supor membrane filter (PALL-Life 










acetonitrile and filled up to the mark. 100 µL of the obtained solutions were injected into a 
HPLC-UV. 
 
2.4 In vitro evaluation of hPTH(1-34) protection by SBTI against enzymatic degradation 
 
This experimental design was based on work by Werle, Samhaber, and Bernkop-Schnürch 
(2006). Briefly, 1.0 mL of 50 mM Tris buffer pH 6.5 containing 1.0 mg hPTH(1-34) acetate either 
with or without 25.1 mg SBTI (resembling the ratio in the formulation) were mixed with 1.0 mL 
of the Tris buffer containing either 0.5 mg trypsin, 0.9 mg chymotrypsin, or neither. Solutions 
were incubated at 37 oC with constant shaking. 250 µL samples were withdrawn at: 2, 5, 10, 15, 
30, and 60 minutes, and immediately mixed with 250 µL of 0.5% TFA to stop by the acidic pH the 
degradative action of the enzymes. Prior to each set of experiments, 125 µL of a hPTH(1-34) 
containing solution (as described above) was mixed with 125 µL of Tris buffer and 250 µL of TFA 
0.5% to imitate the ‘0’ time point. This served as a 100 % from which the degradation was 
calculated. 40 µL were injected into a HPLC-UV. The work was done in duplicate.  
 
2.5 Chromatographic analysis 
 
The separation was performed on a ZORBAX 300SB C-18, 4.6*150 mm column with particle size 
of 3.5 µm (Agilent Technologies Inc., Santa Clara, CA, US; further referred to as Agilent), 
protected by a guard column. The column temperature was maintained at 40 oC and the 
autosampler at 5 oC. Elution of hPTH(1-34) at ~8 min (supplementary Figure S1) was obtained 
with flow of 1.0 mL/min of mobile phase comprised of a 1:3 mixture of acetonitrile : 0.2 M 
sulfate buffer pH 2.3; run time of 15 min. Detection was performed at 214 nm. The work was 
performed on the HPLC system Agilent 1100 series coupled with DAD detector Agilent 1100 
series (Agilent). Results were obtained on the ChemStation for LC 3D systems, Rev.B.04.03-SP1 





All surgical and experimental procedures were reviewed and approved by the Israeli National 
Council for Animal Experimentation (study license number: IL-14-12-362) and comply with the 
8th edition (Animals 2011) of the guidelines of the National Institutes of Health for the care and 
use of laboratory animals. 
 
2.7 Animal model 
 
The study was performed on five female domestic pigs (sus scrofa domesticus) with a mean 
weight of 46 kg, obtained from ‘Yaar Shivuk’, I’billin, Israel. All pigs received each of the three 
formulations, with a washout period of at least a week between the experiments. Formulations 
were administered in the following order: SNAC/SBTI/hPTH(1-34) formulation, SNAC/hPTH(1-34) 
formulation and SBTI/hPTH(1-34) formulation. 48 hours before each experiment, animals were 
fed a liquid diet and fasted overnight, with free access to water, for 12 hours prior to the 
administration of the formulations. All pigs were in good health before each experiment, as 
determined by physical examination. On the morning of the experiment, pigs were sedated by a 
10 : 1 ketamine : xylazine solution, followed by maintenance of 2-3 % isoflurane. Pigs received 5 










acetate (0.69 mg hPTH(1-34) as a free base), was delivered directly to the duodenum of sedated 
animals (Figure 1) by a custom-made endoscope-based device, equipped with a chamber storing 
the formulation, a pneumatic mechanism for the release of the formulation from the chamber, 
and a live-video-camera to ensure repeatable delivery to the same location. In all animals, the 
granulate was released and clustered in an approximately the same location. 
 
Sedation was terminated after approximately 30 min and pigs were enabled to wake up, while 
blood sampling continued. Blood samples of 3 mL were taken via an indwelling cannula in the 
right jugular vein into K3-EDTA vacutainers at the following time points: 10 minutes pre-dose, 
and after formulation administration at 5, 10, 15, 20, 30, 45, 60, 75, 90, 105, 120, and 150 
minutes. A void of 1 mL was drawn and discarded before each sample, and the cannula was 
flushed with 1.5 mL normal saline after each sampling. Samples were kept on ice and 
centrifuged within 0.5 hours at 2540 g, 4 °C for 10 minutes. Plasma was stored at -20 °C pending 
analysis. 
  
2.8 Bioanalytical method 
 
Quantification of plasma hPTH(1-34) was performed using a chemiluminescence-based 
immunoassay on the IDS-iSYS automated platform (Immunodiagnostic Systems, Boldon, UK), at 
the Bioanalytical Facility, University of East Anglia (UK) (Washbourne, Tang, and Fraser 2012). 
Linearity was shown across the range of 4-100 pg/mL (R2>0.997). The lower limit of 
quantification (LLOQ), defined as the lowest quantifiable concentration at which the analytical 
coefficient of variation (CV) was less than 10 %, was determined at 15 pg/mL. The intra-assay CV 
was 5.4 % at  concentration of 46.7 pg/mL and 7.0 % at concentration of 11.7 pg/mL. Inter-assay 
CV was 7 % at concentration of 45.1 pg/mL and 4.2 % at concentration of 18.5 pg/mL. 
 
2.9 Statistical and pharmacokinetic analysis 
 
The area under the curve (AUC) of hPTH(1-34) concentration vs time was calculated by the 
linear trapezoidal rule separately for each pig. Statistical analysis of the pharmacokinetic (PK) 
parameters (Cmax and AUC) was performed by Kruskal-Wallis rank-sum test with Dunn post-hoc 
analysis, further adjusted by the Benjamini-Hochberg FDR method. Statistical significance was 
stated for p≤0.05. 
 
 
3. Results  
 
3.1 In vitro evaluation of hPTH(1-34) protection by SBTI against enzymatic degradation 
 
Table 2 shows in vitro results of SBTI inhibition of hPTH(1-34) proteolysis by trypsin and 
chymotrypsin. hPTH(1-34) alone was shown to be stable for at least one hour. When exposed to 
proteolytic enzymes trypsin and chymotrypsin hPTH(1-34) is rapidly degraded, reaching 
undetectable levels by two minutes, the first time point tested. However, in presence of SBTI 
enzymatic proteolysis was substantially inhibited. Following exposure to trypsin, 92% of the 
initial hPTH(1-34) concentration remained at 15 minutes (Tmax of the in vivo study) and 77% 
after an hour of incubation. Chymotrypsin was less susceptible to SBTI inhibition. Nevertheless, 













Table 2. In vitro study: inhibition by the soybean trypsin inhibitor of teriparatide’s degradation 







Percent of remaining intact hPTH(1-34) 
2 min 5 min 10 min 15 min 30 min 60 min 
hPTH(1-34) 
 
100 ±0 100 ±0 100 ±0 100 ±0 100 ±0 100 ±0 
hPTH(1-34) : trypsin 11.4 : 1.0 0 0 0 0 0 0 
hPTH(1-34) : 
chymotrypsin 6.9 : 1.0 0 0 0 0 0 0 
hPTH(1-34) : trypsin : 
SBTI  11.4 : 1.0 : 149.4 94 ±2 94 ±2 94 ±2 92 ±1 86 ±0 77 ±1 
hPTH(1-34) : 
chymotrypsin : SBTI  6.9 : 1.0 : 90.2 78 ±1 74 ±0 67 ±0 59 ±0 39 ±0 13 ±1 
Mean (±SD); n=2. hPTH(1-34) – teriparatide (as acetate), SBTI – soybean trypsin inhibitor. 
 
3.2  Dissolution test 
 
The in vitro dissolution of the formulations was very rapid (Table 3). 100% of hPTH(1-34) was 
released within 5 minutes after the beginning of the test from the SNAC/SBTI/hPTH(1-34) and 
SNAC/hPTH(1-34) formulations. The SBTI/hPTH(1-34) formulation had a slightly slower 
dissolution rate. Nevertheless, a major part of the SBTI/hPTH(1-34) formulation’s dose (72.6%) 
was released at the 5 min time point.  
 
Table 3. Percent of teriparatide acetate released from the granulate formulations in dissolution 
test. 
Time (min) SNAC/SBTI/hPTH(1-34) SNAC/hPTH(1-34) SBTI/hPTH(1-34) 
0 0.0 (±0.0) 0.0 (±0.0) 0.0 (±0.0) 
5 100.0 (±3.6) 100.0 (±0.0) 72.6 (±8.1) 
10 100.0 (±3.6) 100.0 (±0.0) 93.5 (±0.0) 
15 100.0 (±3.6) 100.0 (±0.0) 100.0 (±6.5) 
20 100.0 (±3.6) 100.0 (±0.0) 100.0 (±0.0) 
Mean (±SD), n=2; SNAC – salcaprozate sodium, SBTI – soybean trypsin inhibitor, hPTH(1-34) – 
teriparatide (as acetate). 
 
3.3 In vivo study in pigs 
 
The PK profile of hPTH(1-34) following the administration of the three tested formulations is 
presented in Figure 2, with the main PK parameters described in Table 4. The formulation 
containing both SNAC and SBTI (SNAC/SBTI/hPTH(1-34) formulation) was shown, with statistical 
significance, to enable higher plasma exposure of hPTH(1-34) compared to the other two 
formulations (~10- and ~20-fold higher Cmax and AUC, respectively, compared to both the other 










34) and SBTI/hPTH(1-34) formulations, both enabling only slight increase in plasma 
concentrations over baseline.  
 
 
Table 4. Mean (±SEM) pharmacokinetic parameters obtained following administration by a 
custom-made endoscope-based device of dry granulate formulations containing 0.75 mg 





Cmax (pg/mL) Tmaxb (min) AUC0-last (min*pg/mL) 
SNAC/SBTI/hPTH(1-34) 5 259.6a (±96.2) 5 (5-15) 5310.8a (2745.8) 
SNAC/hPTH(1-34) 5 28.6 (±16.3) 5 (5) 262.4 (157.1) 
SBTI/hPTH(1-34) 4 9.6 (±5.3) 25 (15-90) 218.5 (158.0) 
SNAC – salcaprozate sodium, SBTI – soybean trypsin inhibitor, hPTH(1-34) – teriparatide (as 
acetate), Cmax – maximal plasma concentration, Tmax – time to reach maximal plasma 
concentration, AUC0-last – area under the curve calculated to the last sampling time point. 
a Differs with statistical significance from the other two groups with p≤0.05 (Kruskal-Wallis rank-
sum test with Dunn post-hoc analysis, further adjusted by the Benjamini-Hochberg FDR 
method). 





The vast majority of biological drugs require parenteral administration due to their inherent 
chemical instability throughout the GIT and negligible permeability across the intestinal 
epithelial lining. In recent years, a concerted effort has been made to overcome these 
absorption challenges and create an oral dosage form of these drugs. Two approaches stand out 
because of their advanced stages of development. One approach is based on the enhancement 
of the drug’s permeability through the epithelial membrane and the second is based on the 
prevention of proteolysis. Each of these individual approaches is capable of augmenting 
systemic exposure of orally delivered peptides and proteins, albeit to a limited extent. In the 
current work, we studied the two methods each on their own, and in combination in vivo in pigs. 
To the best of our knowledge, this is the first report of in vivo evaluation of the combination of 
these two delivery methods utilized for the oral delivery of macromolecules.  
 
An in-depth investigation undertaken by Novo Nordisk A/S on the permeation enhancement 
action of SNAC showed the stomach as the main absorption site for semaglutide (Rybelsus) 
(Buckley et al. 2018). In our current work, we showed in vivo by an example of hPTH(1-34) that a 
peptide drug appropriately co-formulated with SNAC can be also effectively absorbed from the 
small intestine. 
 
Results of the current study showed that hPTH(1-34) delivered only with a protease inhibitor 
(SBTI/hPTH(1-34) formulation), although protected from proteolytic degradation, cannot 
effectively permeate the lipophilic membranes of the epithelial cells due to hydrophilic nature 
and large size. Consequently, its plasma concentrations were almost undetectable. When the 










(SNAC/hPTH(1-34) formulation) an insufficient amount of the intact drug is present in the 
intestinal lumen to be absorbed, as it is rapidly degraded by the intestinal proteolytic enzymes 
and thus, only very low plasma concentrations of hPTH(1-34) were detected. When these two 
approaches are appropriately combined, higher systemic absorption of the peptide can be 
achieved.  
 
As hPTH(1-34) is highly sensitive to proteolysis by the intestinal enzymes trypsin and 
chymotrypsin (Werle, Samhaber, and Bernkop-Schnürch 2006), it was co-formulated with a 
protease inhibitor (SBTI). To evaluate the ability of SBTI to protect hPTH(1-34) from proteolysis, 
an in vitro study was undertaken prior to the study in pigs. Results of the study showed that SBTI 
was highly potent in protecting hPTH(1-34) from proteolysis by trypsin; inhibition of 
chymotrypsin activity was limited but still significant. As SNAC’s effect on membrane 
permeability is relatively short (Buckley et al. 2018), leading to a Tmax of 5-15 minutes (Table 4), 
luminal proteolysis inhibition by SBTI is effective in preserving a major portion of the delivered 
dose of the drug intact. 
 
As the dissolution rate may potentially impact the local concentrations of the permeation 
enhancer, which is critical for effective enhancement of the drug’s absorption (as previously 
discussed), a comparative dissolution test of the three formulations was performed (Table 3). 
For the three tested formulations the dissolution was very fast. Therefore, this factor was not 
included in the analysis of the data; in practical terms, it may be considered as if the 
constituents of the three formulations were released at the application site rapidly and 
simultaneously. Consequently, it can be deduced that the dissolution rate is not the reason for 
the different PK profiles of hPTH(1-34) obtained in the three tested groups in vivo. 
 
Implications of the current study are not limited only to the constituents of the tested 
formulation. We believe that many attempts of per oral delivery of macromolecules undertaken 
in the past were unsuccessful due, at least partially, to a limited understanding of GIT 
physiological mechanisms, resulting in a suboptimal pharmaceutical delivery method. The 
appropriate combination of several absorption enhancing approaches such as those suggested 
here will enable more effective oral delivery of these drugs.  
 
The purpose of the current work was to study the mechanisms of oral delivery of biological 
drugs. Usually, mechanistic studies are performed in in vitro and ex vivo systems, representing 
an isolated tissue or organ of interest, however, the entire biologic system of the intact body, 
including the variety of parameters affecting absorption, is much more complex (Dahan, 
Lennernäs, and Amidon 2012; Wilding 2000). Direct delivery to the duodenum in the current in 
vivo study was performed in order to isolate the effect of the formulation excipients on the 
absorption of hPTH(1-34), preventing the influence of stomach-related physiological processes: 
gastric emptying time, pH, stomach motility, etc. These parameters may potentially bias the 
results and increase their variability, making the interpretation of the data difficult. Yet, when 
directly administering the formulation to the area of interest in vivo, only the relevant 
physiological processes are present, simplifying the understanding of the contribution of the 
formulation components to the absorption process of the studied drug. In current work, the 
variability in the results was still high, probably rising from a known variability of absorption of 
peptide and protein drugs in the GIT (Tyagi, Pechenov, and Subramony 2018). Still, the results 
were found to be statistically significant, enabling rational conclusions for the studied objectives 











Regarding the molecule studied in this work – hPTH(1-34), the PK profile of the oral formulation 
obtained in the current study is of particular interest. While the bioavailability of hPTH(1-34) is 
important for bone homeostasis, the PK profile of hPTH(1-34) is also critical. It is well established 
that intermittent administration of pharmacological doses of hPTH(1-34) has an anabolic effect 
on the bone, while continuous hPTH administration is detrimental for the skeleton due to 
stimulation of bone resorption (Hock and Gera 1992). These PK profiles suggest that the 
anabolic or catabolic response of bone to hPTH(1-34) is determined primarily by the length of 
time that serum concentrations of hPTH(1-34) remain above baseline levels of endogenous PTH 
and only secondarily by the Cmax or AUC of hPTH(1-34) achieved (Frolik et al. 2003). The 
optimal PK profile for an anabolic effect and therapeutic response of hPTH(1-34) is characterized 
by rapid absorption and rapid elimination (Satterwhite et al. 2010), which were also observed in 
the current study with hPTH(1-34) delivered to intestine with the combination of the two 
employed methods. This profile was comparable to the PK profile of a subcutaneous injection 
(Forteo) utilized for the treatment of osteoporotic women (Satterwhite et al. 2010). These 
promising results paved the way for the clinical development of an oral SNAC-SBTI combination-





The current study highlights the potential of an appropriate combination of the two oral drug 
delivery approaches – permeation enhancement and proteolysis inhibition, to effectively 
increase plasma exposure of peptide and protein drugs following peroral administration. This 
combination methodology is yet to be fully exploited and could be further implemented for 
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Figure 1. Delivery of the formulation in the form of a dry granulate (indicated by an arrow) to 
the duodenum by a custom-made endoscope-based device. The size bar shows the dimensions 
of the administered granules. 
 
 
Figure 2. Teriparatide plasma concentration vs. time plot (mean ±SEM) following administration 
of formulations in the form of a dry granulate containing 0.75 mg teriparatide acetate (0.69 mg 
teriparatide as a free base) directly to the duodenum of female pigs by a custom-made 
endoscope-based device; SNAC – salcaprozate sodium, SBTI – soybean trypsin inhibitor, hPTH(1-
34) – teriparatide (as acetate); SNAC/SBTI/hPTH(1-34) formulation: n=5; SNAC/hPTH(1-34) 
















































































 Soybean trypsin inhibitor (SBTI) protects hPTH(1-34) from proteolysis in the intestine 
 SNAC/SBTI combination significantly raises plasma exposure of oral hPTH(1-34)  
 Oral formulation hPTH(1-34)/SNAC/SBTI befits the PK profile for osteoporosis treatment 
 Endoscopic intraduodenal delivery in pigs enables investigation of absorption mechanisms 
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